Last reviewed · How we verify
Autologous MSCs
Autologous mesenchymal stem cells (MSCs) are harvested from the patient's own bone marrow or adipose tissue and administered to promote tissue repair and modulate immune responses.
Autologous mesenchymal stem cells (MSCs) are harvested from the patient's own bone marrow or adipose tissue and administered to promote tissue repair and modulate immune responses. Used for Cartilage defects and osteoarthritis (likely primary indication based on MSC development history).
At a glance
| Generic name | Autologous MSCs |
|---|---|
| Sponsor | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León |
| Drug class | Cell therapy |
| Modality | Small molecule |
| Therapeutic area | Regenerative Medicine / Orthopedics |
| Phase | Phase 3 |
Mechanism of action
MSCs are multipotent cells capable of differentiating into various cell types (osteocytes, chondrocytes, adipocytes) and secreting immunomodulatory factors that reduce inflammation and promote tissue regeneration. When administered autologously, they can home to damaged tissues and facilitate repair through both direct differentiation and paracrine effects. This approach leverages the patient's own cells to minimize rejection risk while harnessing regenerative and anti-inflammatory properties.
Approved indications
- Cartilage defects and osteoarthritis (likely primary indication based on MSC development history)
Common side effects
- Injection site pain or swelling
- Infection at harvest or injection site
- Immune reaction
Key clinical trials
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis (PHASE1, PHASE2)
- Autologous Stem Cell Therapy in Patients With Multiple System Atrophy (PHASE2)
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
- Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
- A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects (PHASE1)
- Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT (PHASE1)
- Investigating the Efficacy of Autologous, Adipose-derived Mesenchymal Stem Cell Therapy for the Treatment of Sexual Function Impairment in Women Aged 40-50 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: